Tackling Endocrine Resistance in Breast Cancer

Video

This video reviews the mechanisms of acquired and upfront endocrine resistance in estrogen receptor–positive breast cancer as well as research into strategies for overcoming this resistance.

In this video, Ingrid A. Mayer, MD, MSCI, of the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, discusses mechanisms of acquired and upfront endocrine resistance in estrogen receptor (ER)-positive breast cancer as well as research into strategies for overcoming these types of resistance, including targeting the mTOR and PI3K pathways.

Mayer spoke on this subject during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
6371178759112
Focused, high-dose radiotherapy doses may prolong survival and the interval to subsequent therapy for patients with advanced prostate cancer.
Related Content